History | Nivolumab for treating advanced (unresectable or metastatic) melanoma | Guidance | NICE

Guidance
Skip Standards and indicators submenu
Quality standards
Our quality standards set out priority areas for quality improvement. They highlight areas with identified variation in current practice.
View our quality standards
How to use our quality standards
The timeline for developing quality standards
Help us develop quality standards
Selecting and prioritising quality standards topics
About quality standards
Indicators
Our indicators measure outcomes that reflect the quality of care, or processes linked by evidence to improved outcomes.
View list of indicators
Learn about the committee that develops indicators
About indicators
Skip Life sciences submenu
Life Sciences
We offer tailored support to industry during product development. Our expertise can help you build the evidence needed to achieve market access.
View life sciences
Get support from NICE
NICE Advice service
Trusted, unrivalled expertise.
Make an enquiry
Contact us to discuss your requirements.
Innovative Licensing and Access Pathway (ILAP)
Streamlining patient access to safe, financially sustainable and innovative medicines.
Learn how we evaluate technologies
Health technology evaluation and topic selection manuals
Updated manuals for methods, processes and topic selection.
Digital health technologies
Accelerating our efforts to deliver innovation to the health and care system.
Evidence standards framework
Using the best available evidence to develop recommendations that guide decisions in health, public health and social care.
Our guidance programmes
Ensuring new technologies are clinically effective and offer economic value.
Register your product
Non-pharmaceutical
NHS Innovation Service is a clear and simple point of entry for health technologies to access support and national evaluation programmes.
Pharmaceutical
UK PharmaScan is a database of new medicines, indications and formulations in the pharmaceutical pipeline.
Find published and proposed evaluations
Diagnostics
Guidance on measurements and tests used to evaluate a patient's condition.
Medical technologies
Guidance on medical technologies put forward to NICE by manufacturers.
Technology appraisals
Guidance on new and existing medicines and treatments in the NHS.
Highly specialised technologies
Guidance on the use of highly specialised medicines and treatments.
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
Skip About submenu
About
NICE helps practitioners and commissioners get the best care to patients, fast, while ensuring value for the taxpayer.
Explore about
Our programmes
Learn about the information we produce.
Guidance
Advice
Quality standards
Indicators
Digital health
Topic selection
Get involved
Understand how decisions are made:
Attend a committee meeting
Comment on draft guidance:
Guidance in consultation
Be part of a guidance committee:
Join a committee
Help develop our products:
Register as a stakeholder
Putting you at the heart of our work:
Public involvement
What we do
Social care
Life sciences
NICE international
Patient safety
Shared decision making
View all What we do
Into practice
Social care quick guides
Measuring the use of NICE guidance
Resource planner
View all Into practice
Who we are
The board
The NICE strategy 2021 to 2026
Corporate publications
View all Who we are
- Contact us
- Jobs

History

Expected publication

Equality Impact Assessment (Guidance development) (PDF 155 KB)

Published:

18 February 2016

Final appraisal determination

Final appraisal determination
Final appraisal determination document (PDF 355 KB)

Published:

22 January 2016
Committee papers (PDF 7.64 MB)

Published:

22 January 2016

Final scope

Final scope
Final scope (PDF 121 KB)

Published:

17 July 2015

Final matrix

Final matrix
Final matrix (PDF 101 KB)

Published:

17 July 2015

NICE response to comments on the draft scope and provisional matrix

NICE response to comments on the draft scope and provisional matrix
NICE response to comments on the draft scope and provisional matrix (PDF 198 KB)

Published:

17 July 2015

Draft scope for consultation (pre-referral) - March 2015

Draft scope for consultation (pre-referral) - March 2015
Draft scope for consultation (pre-referral) - March 2015 (PDF 124 KB)

Published:

03 August 2015

Provisional matrix (pre-referral) - March 2015

Provisional matrix (pre-referral) - March 2015
Provisional matrix (pre-referral) - March 2015 (PDF 103 KB)

Published:

03 August 2015

Melanoma (advanced, unresectable, metastatic) - nivolumab [ID846], [ID847], [ID848]: draft scope for consultation (pre-referral) - March 2015

Melanoma (advanced, unresectable, metastatic) - nivolumab [ID846], [ID847], [ID848]: draft scope for consultation (pre-referral) - March 2015
Melanoma (advanced, unresectable, metastatic) - nivolumab [ID846], [ID847], [ID848]: draft scope for consultation (pre-referral) - March 2015 (PDF 133 KB)

Published:

03 August 2015

Equality impact assessment form

Equality impact assessment form
Equality impact assessment form (PDF 119 KB)

Published:

17 July 2015